The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture

Medical Decision Making

Volumn 29, Issue 6, 2009, Pages 678-689

  Stevenson, Matt D ^a   Oakley, Jeremy E ^b   Lloyd Jones, Myfawny ^a   Brennan, Alan ^a   Compston, Juliet E ^c   McCloskey, Eugene V ^d   Selby, Peter L ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bayesian statistics; Bisphosphonates; Mathematical modeling; Osteoporosis; Value of information

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO;

AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; UNCERTAINTY; UNITED KINGDOM;

BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70449554407     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X09336077     Document Type: Article

References (26)

1. Consensus development conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1991 ; 90: 107-110.
2. Kanis JA, Gluer CC An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000 ; 11: 192-202.
3. Stevenson M., Davis S., Lloyd-Jones M., Beverley C. The clinical effectiveness and cost effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007 ; 11 ( 4 ).
4. National Institute for Health and Clinical Excellence. The Clinical Effectiveness and Cost Effectiveness of Technologies for the Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women. Available from: http://guidance.nice.org.uk/TA87. 5.
5. National Institute for Health and Clinical Excellence. Osteoporosis - Secondary Prevention (Final Appraisal Determination). http://guidance.nice.org. uk/page.aspx?o=437523. Accessed August 2007.
6. Odvina CV, Zerwekh JE, Rao DS, Maalouf N., Gottschalk FA, Pak C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 ; 90: 1294-1301.
7. Stevenson MD, Lloyd-Jones M., De Nigris E., Brewer N., Davis S., Oakley J. A systematic review and economic evaluation of interventions for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005 ; 9 (22). 1-160. Errata at http://www.hta.nhsweb.nhs.uk/project/1381.asp.
8. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisals. 2008. Available from: http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
9. Kind P., Dolan P., Gudex C., Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998 ; 316: 736-741.
10. Kanis JA, Johnell O., Oden A., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004 ; 15: 20-26.
11. The Government Actuary Department. Interim Life Tables. England and Wales. http://www.gad.gov.uk/Life-Tables/Interim-life-tables.htm. Accessed July 2007.
12. Klotzbeucher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000 ; 15: 721-727.
13. University of Sheffield. Matt Stevenson BSc (Lancaster), PhD (Lancaster). Available from: http://www.shef.ac.uk/scharr/sections/heds/staff/stevenson-m. html.
14. National Health Service England and Wales. Electronic Drug Tariff. http://www.ppa.org.uk/edt/August-2007/mindex.htm. Accessed August 2007.
15. Stevenson M., Davis S. Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. 2006. Available from: http://guidance.nice.org.uk/ page.aspx?o=370643.
16. Stevenson MD, Davis SE, Kanis JA The hospitalisation costs and out-patient costs of fragility fractures. Women Health Med. 2006 ; 4 (3). 149-151.
17. Kanis JA, Oden A., Johnell O., De Laet C., Jonsson B. Excess mortality after hospitalization for vertebral fracture. Osteoporos Int. 2004 ; 15: 108-112.
18. Black DM, Schwartz AV, Ensrud KE, et al. Effects of stopping or continuing alendronate after 5 years of treatment. JAMA. 2006 ; 296 (24). 2927-2938.
19. Black DM, Cummings SR, Karpf DB,et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996 ; 348: 1535-1541.
20. British National Formulary. BNF 54 http://www.bnf.org/bnf/ bnf/54/36237.htm?q = %22alendronate%22. Accessed January 2008. 21.
21. OHagan A, Buck CE, Daneshkhah A, et al. Uncertain Judgements: Eliciting Experts Probabilities. Chichester, UK: John Wiley and Sons; 2006.
22. Ades AE, Lu G., Claxton K. Expected values of sample information calculation in medical decision making. Med Decis Making. 2004 ; 24: 207-227.
23. Brennan A., Kharroubi SA, Chilcott J., OHagan A. A two level Monte Carlo approach to calculation expected value of sample information: how to value a research design [Discussion paper]. Available from: http://www.shef.ac.uk/ content/1/c6/02/96/29/evsi.doc. Sheffield, UK: University of Sheffield ; 2002.
24. Brennan A., Kharroubi SA Efficient computation of partial expected value of sample information using Bayesian approximation. J Health Econ. 2007 ; 26: 122-148.
25. Stinnett A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Med Decis Making. 1998 ; 18: S68 - S80.
26. Lloyd Jones M., Wilkinson A. Adverse events and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews. 2006. http://guidance.nice.org.uk/page.aspx?o=370646. Accessed January 2008.